Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711989 | 0.89 | HDAC1 (0.55) | CETPHDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL5706504 | 0.86 | CETP (0.71) | CETPL3MBTL1RAB9AKDM4EALOX12 | |
| SCHEMBL12427249 | 0.85 | PTGS1 (0.55) | HDAC1HDAC3HDAC2MAPK1HDAC4 | |
| SCHEMBL12963094 | 0.82 | LMNA (0.57) | HDAC1HDAC3HDAC2MAPK1HDAC4 | |
| SCHEMBL2087952 | 0.82 | CETP (0.67) | CETPL3MBTL1RAB9AKDM4EALOX12 | |
| SCHEMBL3846828 | 0.81 | PTGS1 (0.58) | HDAC1HDAC3HDAC2MAPK1HDAC4 | |
| SCHEMBL7089699 | 0.81 | RAB9A (0.71) | CETPL3MBTL1RAB9AKDM4EALOX12 | |
| SCHEMBL5839324 | 0.79 | SHMT2 (0.55) | CETPHDAC1HDAC3HDAC2HDAC4 | |
| SCHEMBL27699103 | 0.79 | CETP (0.50) | CETPHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL2301094 | 0.78 | CETP (0.68) | CETPL3MBTL1RAB9AKDM4EALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-05-28 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10246455-B2 | Histone deacetylase inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-04-02 | — | — | US | disclosed |
| US-20170057956-A1 | HISTONE DEACETYLASE INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-03-02 | — | — | US | disclosed |
| US-8802448-B2 | Mixed mode ligands | PALL CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | ASTRAZENECA AB (SE) | 2013-06-27 | — | — | US | disclosed |
| US-20130030154-A1 | MIXED MODE LIGANDS | PALL CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| US-8343996-B2 | Azaquinolinone derivatives and uses thereof | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | FUJIFILM CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7250514-B1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | HDAC1, HDAC3, HDAC4 | CETP 2978/4885HDAC1 1/4885HDAC3 2/4885 |
| US-10246455-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC5 | CETP 3749/4885HDAC1 1/4885HDAC3 4/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CETP 3184/4885HDAC1 1/4885HDAC3 4/4885 |
| US-10851058-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | CETP 1650/4885HDAC1 1/4885HDAC3 3/4885 |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | TPMT, AZI2, NNMT | CETP 3733/4885HDAC1 33/4885HDAC3 40/4885 |
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | CETP 2463/4885HDAC1 1/4885HDAC3 6/4885 |
| US-20130030154-A1 | MIXED MODE LIGANDS | NCL, NECTIN4, NCLN | CETP 4449/4885HDAC1 1112/4885HDAC3 1717/4885 |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | CETP 1650/4885HDAC1 1/4885HDAC3 3/4885 |
| US-20170057956-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC5 | CETP 3749/4885HDAC1 1/4885HDAC3 4/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | CETP 3943/4885HDAC1 5/4885HDAC3 3/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | CETP 1650/4885HDAC1 1/4885HDAC3 3/4885 |
| US-20070202357-A1 | Organic electroluminescent element and compounds for use in the element | RPL31, RPL38, RPL39 | CETP 4473/4885HDAC1 784/4885HDAC3 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.